Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Asset Writedowns and Impairment (2023 - 2025)

Historic Asset Writedowns and Impairment for Maxcyte (MXCT) over the last 3 years, with Q3 2025 value amounting to $360000.0.

  • Maxcyte's Asset Writedowns and Impairment fell 4835.01% to $360000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 1160.31%. This contributed to the annual value of $1.8 million for FY2024, which is 15408.9% up from last year.
  • Maxcyte's Asset Writedowns and Impairment amounted to $360000.0 in Q3 2025, which was down 4835.01% from $100000.0 recorded in Q2 2025.
  • Maxcyte's 5-year Asset Writedowns and Impairment high stood at $937000.0 for Q4 2024, and its period low was -$9000.0 during Q3 2023.
  • For the 3-year period, Maxcyte's Asset Writedowns and Impairment averaged around $307000.0, with its median value being $130000.0 (2024).
  • Its Asset Writedowns and Impairment has fluctuated over the past 5 years, first skyrocketed by 784444.44% in 2024, then plummeted by 5000.0% in 2025.
  • Quarter analysis of 3 years shows Maxcyte's Asset Writedowns and Impairment stood at $476000.0 in 2023, then skyrocketed by 96.85% to $937000.0 in 2024, then tumbled by 61.58% to $360000.0 in 2025.
  • Its last three reported values are $360000.0 in Q3 2025, $100000.0 for Q2 2025, and $65000.0 during Q1 2025.